Rocket Pharmaceuticals
RCKT
76 hedge funds and large institutions have $664M invested in Rocket Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 13 closing their positions.
162% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 13
152% more capital inflows, than outflows
Capital inflows: $101M | Capital outflows: $40.1M
36% more funds holding
Funds holding: 56 → 76 (+20)
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
7.6% more ownership
Funds ownership: 78.53% → 86.13% (+7.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.1M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.52M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.75M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.81M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$9.46M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$6.56M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.07M |
| 4 |
Highbridge Capital Management
New York
|
-$4.69M |
| 5 |
Goldman Sachs
New York
|
-$2.52M |
RCKT Hedge Fund Activity: Q2 2018 in Review
76 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2018, worth a combined $664M — up 19% from $558M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new RCKT positions and 13 closed out — a net gain of 21 holders — while 19 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $23.1M. The largest seller was Ghost Tree Capital, cutting an estimated $9.46M.
- 76 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2018, up from 56 in Q1 2018.
- Funds reported $664M of Rocket Pharmaceuticals stock for Q2 2018, up 19% quarter-over-quarter.
- 34 funds opened new Rocket Pharmaceuticals positions in Q2 2018 and 13 closed out, a net change of +21 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $23.1M added.
- The largest Rocket Pharmaceuticals seller in Q2 2018 was Ghost Tree Capital, an estimated $9.46M sold.
Based on aggregated 13F filings for Q2 2018.